Trial ID or NCT#
NCT01728805
Status
Purpose
The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
Official Title
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Youn H Kim, MD
Dermatologic oncologist,
Cutaneous oncology specialist,
Dermatologist
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Sunil Arani Reddy
Medical oncologist,
Cutaneous oncology specialist
Clinical Assistant Professor, Medicine - Oncology
Contact us to find out if this trial is right for you.
CONTACT
CCTO
(650) 498-7061
View on ClinicalTrials.gov